南京医药
(600713)
| 流通市值：67.43亿 | | | 总市值：68.59亿 |
| 流通股本：12.87亿 | | | 总股本：13.09亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 14,246,884,352.7 | 53,696,173,895.8 | 40,938,180,822.52 | 27,232,110,530.43 |
| 营业收入 | 14,246,884,352.7 | 53,696,173,895.8 | 40,938,180,822.52 | 27,232,110,530.43 |
| 二、营业总成本 | 13,943,368,597.83 | 52,651,384,912.88 | 40,123,096,334.31 | 26,666,946,892.11 |
| 营业成本 | 13,397,551,742.47 | 50,323,077,943.02 | 38,414,540,220.25 | 25,552,871,035.22 |
| 税金及附加 | 28,768,607.11 | 116,270,967.76 | 85,321,921.41 | 54,788,761.23 |
| 销售费用 | 291,361,696.08 | 1,148,152,134.81 | 845,968,276.41 | 557,873,681.7 |
| 管理费用 | 98,418,095.61 | 517,660,434.62 | 346,175,353.89 | 209,416,358.44 |
| 研发费用 | 9,115,551.48 | 30,635,024.74 | 30,536,340.65 | 22,290,489.93 |
| 财务费用 | 118,152,905.08 | 515,588,407.93 | 400,554,221.7 | 269,706,565.59 |
| 其中:利息费用 | 69,466,148.85 | 325,820,558.4 | 266,514,175.23 | 170,525,181.31 |
| 其中:利息收入 | 6,069,321.19 | 13,605,914.39 | 10,172,311.34 | 6,395,645.21 |
| 加:公允价值变动收益 | 353,888.89 | - | - | - |
| 加:投资收益 | 178,683.57 | 4,018,269.49 | 3,096,723.62 | 1,038,058.45 |
| 资产处置收益 | 2,921,757.69 | 4,149,625.86 | 4,301,998.51 | 4,037,344.55 |
| 资产减值损失(新) | 2,164,228.26 | -18,267,214.45 | -2,124,236.1 | -4,920,761.62 |
| 信用减值损失(新) | -41,738,533.1 | -41,934,892.82 | -68,814,673.14 | -33,852,885.36 |
| 其他收益 | 7,548,166.51 | 30,649,336.29 | 20,063,924.66 | 14,061,127.87 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 274,943,946.69 | 1,023,404,107.29 | 771,608,225.76 | 545,526,522.21 |
| 加:营业外收入 | 7,717,490.51 | 12,410,842.01 | 8,418,950.45 | 7,915,006.84 |
| 减:营业外支出 | 6,325,837.47 | 32,419,560.8 | 17,472,745.23 | 12,558,709.97 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 276,335,599.73 | 1,003,395,388.5 | 762,554,430.98 | 540,882,819.08 |
| 减:所得税费用 | 60,752,142.38 | 260,275,394.61 | 198,747,894 | 143,338,410.13 |
| 六、净利润 | 215,583,457.34 | 743,119,993.89 | 563,806,536.98 | 397,544,408.95 |
| 持续经营净利润 | 215,583,457.34 | 743,119,993.89 | 563,806,536.98 | 397,544,408.95 |
| 归属于母公司股东的净利润 | 177,360,973 | 570,627,552.6 | 441,882,390.22 | 311,321,223.12 |
| 少数股东损益 | 38,222,484.34 | 172,492,441.29 | 121,924,146.76 | 86,223,185.83 |
| (一)基本每股收益 | 0.14 | 0.44 | 0.34 | 0.24 |
| (二)稀释每股收益 | 0.14 | 0.44 | 0.34 | 0.24 |
| 八、其他综合收益 | -7,229,191.85 | 12,772,851.86 | 28,155,158.32 | -7,698,594.37 |
| 归属于母公司股东的其他综合收益 | -6,878,094.3 | 12,572,743.16 | 27,157,780.85 | -8,110,084.78 |
| 九、综合收益总额 | 208,354,265.49 | 755,892,845.75 | 591,961,695.3 | 389,845,814.58 |
| 归属于母公司股东的综合收益总额 | 170,482,878.7 | 583,200,295.76 | 469,040,171.07 | 303,211,138.34 |
| 归属于少数股东的综合收益总额 | 37,871,386.79 | 172,692,549.99 | 122,921,524.23 | 86,634,676.24 |
| 公告日期 | 2025-04-30 | 2025-04-10 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |